Whitehawk Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Whitehawk Therapeutics Inc WHWK.OQ reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -54 cents. The mean expectation of three analysts for the quarter was for earnings of 49 cents per share. Wall Street expected results to range from -45 cents to $2.10 per share.

• Reported revenue was zero​; analysts expected $33.33 million.

• Whitehawk Therapeutics Inc's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of $52.62 million.

• Whitehawk Therapeutics Inc shares had fallen by 3.7% this quarter and lost 42.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 9.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $2.00, about 10% above its last closing price of $1.80

This summary was machine generated from LSEG data August 7 at 05:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)